---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-026262"
form_type: "8-K"
ticker: "APYX"
cik: "0000719135"
company_name: "Apyx Medical Corp"
filed_at: "2026-08-06T20:09:28+00:00"
generated_at: "2026-08-06T20:12:22.222400+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Apyx Medical Q2 revenue $13.9M (+22% YoY); Surgical Aesthetics up 28%; reaffirms FY guidance

## Summary
- Total revenue $13.9M vs $11.4M in Q2 2025; Surgical Aesthetics segment grew 28% to $12.4M.
- Net loss narrowed to $3.2M ($0.07/sh) from $3.8M ($0.09/sh); Adjusted EBITDA loss improved to $0.7M from $2.0M.
- Reaffirmed FY2026 revenue guidance $59.0M-$60.0M; Surgical Aesthetics expected $54.0M-$55.0M.
- Limited commercial launch of power liposuction handpiece for AYON platform began in June 2026 after FDA clearance.
- Cash and equivalents $27.6M; management expects to yield cash through 2027.

## SEC filing metadata
- accession: 0001437749-26-026262
- form_type: 8-K
- ticker: APYX
- cik: 0000719135
- company_name: Apyx Medical Corp
- filed_at: 2026-08-06T20:09:28+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/719135/000143774926026262/0001437749-26-026262-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/719135/000143774926026262/apyx20260602_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-026262
- JSON: https://secwatch.observer/filing/0001437749-26-026262.json
- Plain text: https://secwatch.observer/filing/0001437749-26-026262.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.